Clinical Trial Update: Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BIBW 2992 (neratinib), an irreversible EGFR and HER-2 inhibitor, in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBW 2992 (afatinib)

Snippet

Sponsor: Instituto Nacional de Cancerologia de Mexico | Conditions: Non-Small Cell Lung Cancer, EGFR | Phase 2 | Status: COMPLETED